efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial | Diabetologia Efficacy and safety of tirzepatide

Moreover, the development of DR after 6 years was 7.7% for the MIT group and 32.0% for the CIT group in the primary-prevention cohort (no microvascular disease at baseline) (P = 0.039), and progression of DR occurred in 19.2% of the MIT group and 44.0% of the CIT group in the secondary-intervention cohort (microvascular disease at baseline) (P = 0.049)

Common contributing factors include: Chronic constipation and straining during bowel movements Prolonged sitting on the toilet Diarrhea and frequent bowel movements Increased intra-abdominal pressure Given that Zepbound commonly causes both constipation (in approximately 16-17% of patients) and diarrhea (in about 18-24% of patients), these gastrointestinal effects could theoretically contribute to hemorrhoid development or worsening in susceptible individuals

For detailed discussion about how to start your own medical weight loss practice, please go to our Medical Weight Loss Training course

But it should only be used under medical supervision

The clinical evidence says something close to the opposite

Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors